GlassScriptPhysician profile
Paul M Mitchell
NPI 1265668180
$18,811.91
in general payments reported to CMS, 2019-2025
14 companies · $5,442 in 2025
The $5,442 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $1,787 · 2023: $2,623 · 2024: $8,566 · 2025: $5,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,297 · Food and Beverage: $6,021 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,296.97 |
| Food and Beverage | $6,021.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,312.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,740.14 | 2021-2025 | General - Therapies, Wavewriter Alpha Prime 16, Intracept |
| Curonix LLC | $2,034.76 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $1,381.93 | 2022-2025 | |
| Mml US, INC. | $400.18 | 2023 | Reactiv8 |
| Painteq LLC | $400.15 | 2023-2024 | Painteq |
| Relievant Medsystems, INC. | $367.71 | 2023 | Intracept |
| Hikma Pharmaceuticals USA | $135.40 | 2022 | |
| Collegium Pharmaceutical, INC. | $95.49 | 2022-2024 | Xtampza, Belbuca |
| Allergan, INC. | $75.68 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.56 | 2023-2024 | Relistor |
| Dexcom, INC. | $40.20 | 2024-2025 | Dexcom G6 Transmitter |
| Redhill Biopharma INC. | $30.86 | 2021-2022 | |
| Pfizer INC. | $30.35 | 2023-2024 | |
| Virtus Pharmaceuticals LLC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.